Invasive fungal infections - infections of the bloodstream and organs within the body (e.g. meningitis, pneumonia, peritonitis) - are important causes of morbidity and mortality in liver, pancreas, heart, kidney and lung (i.e. solid organ) transplant recipients. This review found that fluconazole, used as a preventive drug, significantly reduced the number of invasive fungal infections in liver transplant patients. More studies are needed to determine how effective antifungal drugs are for pancreas, heart, kidney and lung transplant patients.
Antifungal drugs used for prevention can significantly reduce the number of invasive fungal infections in liver transplant patients
8 July 2009
This record should be cited as:
Playford EG, Webster AC, Craig JC, Sorrell TC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD004291. DOI: 10.1002/14651858.CD004291.pub2
Assessed as up to date:
22 November 2005
More like this
- Pre-emptive treatment with antiviral agents can help to reduce the risk of cytomegalovirus disease
- Antiviral drugs used as protective and preventive therapy reduce CMV disease and CMV-associated deaths in solid organ transplant recipients
- Prophylaxis with Immunoglobulin G (IgG), anti CMV vaccine or interferon do not significantly reduce CMV disease and CMV-associated mortality in solid organ transplant recipients
- Which drugs are most effective to prevent tuberculosis in organ transplant recipients?
- [Plain language title]